+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Therapy Trends: Rheumatoid Arthritis -- Consensus Outlook Module

  • ID: 2584085
  • Report
  • June 2013
  • Region: Global
  • 133 Pages
  • FirstWord Publishing
1 of 2
Analyse the latest global RA market players and products, and start mapping your future market parameters with Therapy Trends’ Consensus Outlook: Rheumatoid Arthritis, which includes the following comprehensive resources:

- An in-depth 5-year forecast report based on analyst consensus
- Detailed data spreadsheets comparing critical market parameters
- Regular updates over the next 12 months, after major market events

Consensus Outlook Module Features:

- Historical RA sales from 2007–2012
- Forecast RA sales from 2013-2017
- Key competitors and drug developers
- Predicted product positioning
- Current and late-stage pipeline drugs
- Future event mapping to forecast data points
- Comparative clinical trial results

Meticulous Methodology:

- Consensus Outlook: Rheumatoid Arthritis is a data analysis module compiled from meticulous FirstWord research. Its historical sales data (2007–12) is based on company information. The five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

- This Consensus Outlook collates and evaluates the latest relevant reports and forecasts published by leading equity research analysts. This information is fed into the Therapy Trends Forecast model to give unbiased consensus forecasts.

- Overall, this module offers you independent, unbiased, accurate forecasts from leading financial institutions with the most intimate commercial knowledge of the competitive players and products in this disease sector.
Forecast Spreadsheets

- Save valuable time by focusing on FirstWord’s 5-year RA forecast data with our detailed Excel spreadsheets. Consensus Outlook: Rheumatoid Arthritis allows you to quickly compare various market parameters by:

- Market size
- International and US markets
- Product sales
- Brand, company and drug class
- Company forecasts
- Mechanism of action

Consensus Outlook Benefits:

- Chart predicted market growth and product sales
- Map your own market parameters
- Tailor your strategic and investment focus
- Assess your current and future sales resources
- Set proactive launches and branding strategies
Note: Product cover images may vary from those shown
2 of 2
Consensus Outlook

Interactive Data Analysis File (Excel)

Tabs:
— Market size
— Product sales
— Company forecast
— Mechanism of action
— Events

Market Analysis File (PDF)

Contents:

— FirstWord Analysis Highlights
— Rheumatoid Arthritis marketplace
— Key Rheumatoid Arthritis developers
— Rheumatoid arthritis class dynamics
— Enbrel (etanercept; Amgen/Pfizer/Takeda) forecast
— Humira (adalimumab; Abbott/Eisai) forecast
— Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) forecast
— Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./ Mitsubishi Tanabe) forecast
— Cimzia (certolizumab; UCB) forecast
— Orencia (abatacept; Bristol-Myers Squibb) forecast
— Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) forecast
— Actemra/RoActemra (tocilizumab; Chugai/Roche) forecast
— Tofacitinib (CP-690,550; Pfizer/Takeda) forecast
— Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) forecast
— Secukinumab (AIN457; Novartis) forecast

Figures:
— Rheumatoid Arthritis worldwide market sales value, 2006–2016
— Growth and market share of the US and international RA markets, 2006–16
— Rheumatoid Arthritis worldwide market sales value, 2006–2016
— Rheumatoid Arthritis worldwide market share difference from 2006 to 2016
— Rheumatoid Arthritis worldwide market sales value split by class, 2011
— Sales dynamics of leading Alzheimer’s disease brands, 2011-2016
— Sales dynamics of Enbrel (etanercept; Amgen/Pfizer/Takeda), 2006-2016
— Enbrel (etanercept; Amgen/Pfizer/Takeda) sales by region worldwide ($m), 2006–2016
— Sales dynamics of Humira (adalimumab; Abbott/Eisai), 2006-2016
— Humira (adalimumab; Abbott/Eisai) sales by region worldwide ($m), 2006–2016
— Sales dynamics of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2006-2016
— Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide ($m), 2006–2016
— Sales dynamics of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2009-2016
— Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide ($m), 2009–2016
— Sales dynamics of Cimzia (certolizumab; UCB), 2009-2016
— Cimzia (certolizumab; UCB) sales by region worldwide ($m), 2009–2016
— Sales dynamics of Orencia (abatacept; Bristol-Myers Squibb), 2006-2016
— Orencia (abatacept; Bristol-Myers Squibb) sales by region worldwide ($m), 2009–2016
— Sales dynamics of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai), 2006-2016
— Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) sales by region worldwide ($m), 2009–2016
— Sales dynamics of Actemra/RoActemra (tocilizumab; Chugai/Roche), 2006-2016
— Actemra/RoActemra (tocilizumab; Chugai/Roche) sales by region worldwide ($m), 2009–2016
— Sales dynamics of tofacitinib (CP-690,550; Pfizer/Takeda), 2012-2016
— Tofacitinib (CP-690,550; Pfizer/Takeda) sales by region worldwide ($m), 2012–2016
— Sales dynamics of fostamatinib disodium (R788), 2011-2016
— Sales dynamics of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals), 2014-2016
— Sales dynamics of secukinumab (AIN457; Novartis), 2014-2016
— Secukinumab (AIN457; Novartis) sales by region worldwide ($m), 2014–2016

Tables:
— Sales and growth of regions for Rheumatoid Arthritis, 2011–2016
— Leading companies in the branded worldwide Rheumatoid Arthritis market, 2011–2016
— Sales and growth of classes in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factors on the global revenues of Enbrel (etanercept; Amgen/Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factors on the global revenues of Humira (adalimumab; Abbott/Eisai) in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factors on the global revenues of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factors on the global revenues of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factors on the revenues of Cimzia (certolizumab; UCB) in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factors on the revenues of Orencia (abatacept; Bristol-Myers Squibb) in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factors on the revenues of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factors on the revenues of Actemra (tocilizumab) in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factors on the revenues of tofacitinib (CP-690,550; Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factors on the revenues of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) in Rheumatoid Arthritis, 2011–2016
— Expected key impacting factor
Note: Product cover images may vary from those shown
Adroll
adroll